Nuvation Bio Inc. (NUVB)

Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: United States
Exchange: NYSE
Market cap: $2.06B

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

Latest financial period: June 30, 2026
Filed with the SEC: August 6, 2026
Estimated earnings date: November 2, 2026

Not currently ranked. Cannot calculate: sales growth, FCF yield

Menu

Home

Compare

Next Earnings Reports

How this site works

Terms of use

About